Ozempic for Kidney Protection: Evidence Summary and Off-Label Status
What is the current approved use?
On January 28, 2025, Ozempic's US approval expanded to include reducing the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Approval announcement
This indication is included in the current prescribing information for the injection. It is separate from Ozempic's glucose-control and cardiovascular indications. The kidney indication does not mean Ozempic is approved for every cause of kidney disease or for all people with reduced eGFR. Current prescribing information
For an individual decision, document both the diabetes diagnosis and the kidney findings. Albumin in the urine and estimated filtration rate describe different aspects of kidney health and should be reviewed together.
What did FLOW show?
FLOW randomized 3,533 adults with type 2 diabetes and CKD to semaglutide 1 mg weekly or placebo. Median follow-up was 3.4 years. The primary outcome combined kidney failure, a sustained reduction in eGFR of at least 50%, or death from kidney or cardiovascular causes. Perkovic et al., 2024
There were 331 first events among 1,767 semaglutide participants, compared with 410 among 1,766 placebo participants. The hazard ratio was 0.76, with a 95% confidence interval of 0.66-0.88. This is the source of the reported 24% relative reduction. It is not a 24-percentage-point reduction and does not mean kidney function improved by 24%. FLOW publication
The annual eGFR decline was slower by 1.16 mL/min/1.73 m² per year with semaglutide. Slower decline is a useful treatment outcome even if an individual's eGFR does not rise. The study stopped early after a prespecified interim analysis met its efficacy criterion. FLOW publication
Who was enrolled?
FLOW studied two main kidney-function and albuminuria groups:
| Baseline eGFR, mL/min/1.73 m² | Urine albumin-to-creatinine ratio, mg/g |
|---|---|
| 50-75 | Above 300 and below 5,000 |
| 25 to below 50 | Above 100 and below 5,000 |
These are trial-entry criteria, not a replacement for the approved indication or a complete prescribing rule. They help explain which patients directly contributed to the result. FLOW publication
The trial was conducted alongside standard care. Most participants were taking an ACE inhibitor or ARB; approximately 16% used an SGLT2 inhibitor at baseline. A treatment plan should account for that background rather than interpret the result as evidence for stopping established kidney medicines. FLOW baseline report
Where does Ozempic fit with other kidney treatments?
The 2026 American Diabetes Association Standards of Care recommend a GLP-1 agonist with demonstrated benefit to reduce kidney progression and cardiovascular risk in people with type 2 diabetes and CKD. This is current guidance, not a recommendation that remains pending. The same guidance addresses SGLT2 inhibitors and appropriately selected blood-pressure and kidney therapies. ADA 2026 CKD guidance
These medicines address overlapping clinical goals, so the plan depends on existing treatment, kidney stage, albuminuria, blood pressure, glucose and tolerability. The existence of several useful options does not create one automatic sequence for every patient.
The FLOW subgroup analysis also needs accurate interpretation. Among 550 participants already using an SGLT2 inhibitor, the primary-outcome estimate was imprecise: hazard ratio 1.07, 95% confidence interval 0.69-1.67. The statistical test did not establish a different treatment effect by baseline SGLT2 use. This subgroup alone cannot prove a particular additional percentage benefit from the combination. FLOW SGLT2 analysis
For a medication review, identify why each drug is present and which outcome is being followed. Do not assume that adding semaglutide makes an ACE inhibitor, ARB or SGLT2 inhibitor unnecessary.
What dose is used for the kidney indication?
The injection label specifies 1 mg once weekly as the maintenance dose for adults with type 2 diabetes and CKD. The schedule starts at 0.25 mg weekly for four weeks, then 0.5 mg; advancement to 1 mg follows at least four weeks at 0.5 mg. Reduced kidney function alone does not require a dose adjustment. Ozempic prescribing information
The fact that higher doses are available for other treatment goals does not establish a larger kidney benefit from increasing beyond the studied kidney dose. The prescribing decision should account for tolerability and the full treatment plan.
What about people without diabetes?
There is randomized semaglutide evidence outside diabetes, but it comes from a different population and regimen. SELECT enrolled 17,604 people with overweight or obesity and established cardiovascular disease, without diabetes, using semaglutide 2.4 mg weekly or placebo. Its prespecified kidney analysis found the main kidney composite in 1.8% versus 2.2%, respectively, with a hazard ratio of 0.78. That composite included persistent macroalbuminuria as well as more severe kidney outcomes. Colhoun et al., 2024
This is useful evidence for the population studied. It should not be relabeled as a FLOW result, a trial of Ozempic 1 mg in all nondiabetic CKD, or a separate approval for every kidney diagnosis.
A 2026 participant-level analysis pooled SELECT, FLOW and SOUL, totaling 30,787 participants across injected and oral regimens. The pooled kidney composite had a hazard ratio of 0.84; a narrower outcome excluding cardiovascular death also favored semaglutide. The analysis adds context across the populations studied, but it does not make the formulations, doses or approved uses interchangeable. Mann et al., 2026
What should be monitored?
Follow both the kidney condition and treatment tolerance. ADA's 2026 guidance recommends checking eGFR and urinary albumin one to four times yearly in CKD, depending on stage. Extra assessment depends on clinical changes, symptoms and other medicines. ADA 2026 CKD guidance
A useful follow-up record includes:
- eGFR and UACR, with dates and prior values.
- Blood pressure, glucose measures and weight trend.
- The current kidney, blood-pressure and diabetes medicines.
- Nausea, vomiting, diarrhea, fluid intake and any change in urination.
- Potassium results when relevant to the kidney condition and accompanying treatment.
Do not automatically call a new eGFR fall an expected semaglutide effect. Assess its size, timing, hydration and clinical context. The appropriate response differs from the interpretation of a stable long-term trend.
Side effects relevant to kidney care
Vomiting or diarrhea can cause volume depletion and acute kidney injury. Contact the treating team promptly if fluids cannot be kept down, urination falls or significant lightheadedness develops; there is no reason to wait for a fixed 24-hour threshold. Confusion, fainting or severe illness needs urgent assessment.
The existing eligibility review also includes personal or family history of medullary thyroid carcinoma, MEN2, serious allergy to semaglutide or its ingredients, and severe gastroparesis. These are not defined by whether the prescription is intended for glucose or kidney benefit. Ozempic prescribing information
Discuss an illness plan with the prescriber for the entire medication list. Which medicines need temporary adjustment during dehydration depends on the clinical circumstances; it should not be reduced to a blanket instruction to stop all kidney treatment.
Coverage and the treatment discussion
A prescription within the approved kidney population should not automatically be described as off-label. Coverage still depends on the plan's requirements and the documented clinical situation. The useful next step is checking the actual plan criteria with the treating team, not assuming that all kidney-directed prescriptions are excluded.
Frequently asked questions
Is Ozempic kidney protection still off-label?
Does a 24% relative reduction mean kidney function improves by 24%?
Does Ozempic replace my other kidney medicines?
Is there kidney research in people without diabetes?
Should I wait a day before reporting vomiting and reduced urination?
References
- Novo Nordisk. January 28, 2025 kidney-indication approval announcement.
- Novo Nordisk. Current Ozempic injection prescribing information.
- Perkovic et al. FLOW kidney outcomes trial. New England Journal of Medicine, 2024.
- Rossing et al. FLOW rationale, design and baseline data. 2023.
- American Diabetes Association. CKD and risk management: Standards of Care, 2026.
- FLOW analysis by baseline SGLT2 inhibitor use. Nature Medicine, 2024.
- Colhoun et al. SELECT kidney outcomes. Nature Medicine, 2024.
- Mann et al. Pooled kidney outcomes from SELECT, FLOW and SOUL. 2026.